Remicade / Flixabi / Inflectra / Remsima / Zessly - direct healthcare professional communication (DHPC)

infliximab

About

This direct healthcare professional communication (DHPC) contains important information for healthcare professionals prescribing, dispensing or administering the medicine(s). It also includes a communication plan with details of intended recipients and the dissemination date.

Documents

Direct healthcare professional communication (DHPC): Infliximab (Remicade, Flixabi, Inflectra, Remsima and Zessly): Use of live vaccines in infants exposed in utero or during breastfeeding

Key facts

• Medicine name:
  • Remicade
  • Flixabi
  • Inflectra
  • Remsima
  • Zessly
• Active substance:
  infliximab
• Therapeutic area (MeSH):
  • Spondylitis, Ankylosing
  • Arthritis, Rheumatoid
  • Psoriasis
  • Crohn Disease
  • Arthritis, Psoriatic
  • Colitis, Ulcerative
• Procedure number:
  EMEA/H/C/000240/IB/233
• Regulatory outcome:
  Variation
• DHPC type:
  New contraindication
• Human ATC codes:
  L04AB02
• Dissemination date:
  07/03/2022